HER2-positive breast cancer in patients with BRCA1/2 pathogenic variants: Case series and literature review

Article / By

This case series examines three patients with BRCA1/2 pathogenic variants who developed HER2-positive breast cancers, highlighting their treatment responses and reviewing existing literature on the association between these variants and HER2-positive cancers. The findings suggest that while HER2-positive breast cancer is rare in this population, it may be primarily driven by the HER2 oncogenic pathway, with potential implications for treatment strategies, including the combination of olaparib and trastuzumab for patients who have not responded to HER2-targeted therapies.

HER2-positive breast cancer in patients with BRCA1/2 pathogenic variants: Case series and literature review Read More »

Larotrectinib in NTRK3 fusion–positive metastatic secretory carcinoma of the breast: A case study

Article / By

This case study discusses a patient with recurrent metastatic triple-negative breast cancer (TNBC) that was responsive to the TRK inhibitor larotrectinib. TNBC is known for its aggressive nature and poor prognosis, particularly in treatment-resistant cases.

Larotrectinib in NTRK3 fusion–positive metastatic secretory carcinoma of the breast: A case study Read More »

Lichenoid dermatitis induced by abemaciclib in a patient with HR+/HER2- breast cancer

Article / By

This case report describes a rare occurrence of lichenoid dermatitis in a 48-year-old woman with HR+/HER2- breast cancer following treatment with the CDK4/6 inhibitor abemaciclib. The patient experienced skin lesions that resolved after stopping the medication and using topical corticosteroids, emphasizing the importance of recognizing dermatologic side effects associated with these treatments.

Lichenoid dermatitis induced by abemaciclib in a patient with HR+/HER2- breast cancer Read More »

Assessing the long-term prognostic ability of the 70 gene expression signature MammaPrint in an Italian single-center prospective cohort study of early-stage intermediate-risk breast cancer patients

Article / By

This study assessed the prognostic performance of the 70-gene signature MammaPrint in early-stage intermediate-risk breast cancer patients. Results showed that patients with MammaPrint Low Risk tumors had significantly better distant metastasis-free survival and overall survival compared to those with High Risk tumors, supporting the use of MammaPrint for personalized treatment decisions.

Assessing the long-term prognostic ability of the 70 gene expression signature MammaPrint in an Italian single-center prospective cohort study of early-stage intermediate-risk breast cancer patients Read More »

The usefulness of CanAssist Breast over Ki67 in breast cancer recurrence risk assessment

Article / By

The study compares the prognostic performance of CanAssist Breast (CAB) with Ki67 in assessing breast cancer recurrence risk. Results indicate that CAB offers superior prognostic information, particularly for patients in the intermediate Ki67 range, with a higher percentage of low-risk classifications and similar distant relapse-free intervals compared to Ki67.

The usefulness of CanAssist Breast over Ki67 in breast cancer recurrence risk assessment Read More »

Surgical Management of Breast Cancer Liver Metastasis

Article / By

Hepatic resection for isolated breast cancer liver metastases can lead to improved disease-free intervals and overall survival in carefully selected patients. For those not eligible for surgery, ablative therapies combined with systemic chemotherapy are beneficial. The article reviews the effectiveness of these treatments and their long-term outcomes

Surgical Management of Breast Cancer Liver Metastasis Read More »

The optimal timing of breast cancer surgery after COVID-19 infection: an observational study

Article / By

This observational study assesses the risk of postoperative complications in breast cancer patients who had COVID-19 infection, highlighting that surgery within two weeks of infection is associated with a higher complication rate (17.65%) compared to surgery performed two weeks or more after infection (5.51%). The findings suggest caution in timing surgery after COVID-19, although surgery may still be recommended after two weeks due to the manageable nature of complications and no adverse effects on subsequent anti-tumor therapy.

The optimal timing of breast cancer surgery after COVID-19 infection: an observational study Read More »

Genomic tests for risk stratification in patients with early human epidermal growth factor receptor 2-positive breast cancer

Article / By

This review focuses on the advancements in genomic tests for risk stratification in early HER2-positive breast cancer, highlighting the HER2DX assay’s ability to provide prognostic information and predict pathological complete response in patients undergoing neoadjuvant treatment. The assay shows promise in maintaining predictive capabilities even with chemotherapy-free regimens, aiding in the selection of patients for treatment de-escalation.

Genomic tests for risk stratification in patients with early human epidermal growth factor receptor 2-positive breast cancer Read More »

Concordant and discordant breast density patterns by different approaches for assessing breast density and breast cancer risk

Article / By

The study investigates discrepancies in breast density assessments by radiologists, LIBRA software, and an AI algorithm, and their correlation with breast cancer risk among 74,610 Korean women. It finds that the highest breast cancer risk is associated with concordant dense breasts, while discordant cases also show significantly elevated risks, particularly when classified as dense by AI or LIBRA.

Concordant and discordant breast density patterns by different approaches for assessing breast density and breast cancer risk Read More »

Incidence and risk factors of pain following breast cancer surgery: a retrospective national inpatient sample database study

Article / By

This study analyzed 39,870 cases of breast cancer surgery from 2015 to 2019 to assess the incidence and risk factors of postoperative pain (PP), finding an overall occurrence of 6.15%. Significant factors associated with PP included younger age, non-elective admissions, and various comorbidities, highlighting the need for targeted care management to improve patient outcomes.

Incidence and risk factors of pain following breast cancer surgery: a retrospective national inpatient sample database study Read More »

Start typing and press enter to search

This site is only for use by healthcare professionals.

By continuing to view this site you are confirming that you are a healthcare professional.

Confirm